Revive Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Revive Therapeutics şirketinin toplam hissedar öz sermayesi CA$7.2M ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$10.6M ve CA$3.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$773.07k
Eşitlik	CA$7.23m
Toplam yükümlülükler	CA$3.40m
Toplam varlıklar	CA$10.64m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RVVT.F 'nin kısa vadeli varlıkları ( CA$1.1M ) kısa vadeli yükümlülüklerini ( CA$3.3M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: RVVT.F şirketinin kısa vadeli varlıkları ( CA$1.1M ) uzun vadeli yükümlülüklerini ( CA$79.9K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RVVT.F borçsuzdur.

Borcun Azaltılması: RVVT.F un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RVVT.F şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: RVVT.F un, serbest nakit akışı her yıl % 20.1 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Revive Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Ltd. Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Ltd. Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long Covid

Revive Therapeutics Ltd. Provides Update from FDA Meeting for Long Covid Diagnostic Product

Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Ltd. announced that it has received CAD 2.10061 million in funding

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

Revive Therapeutics Ltd. announced that it expects to receive CAD 3 million in funding

Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine

Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development

Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development

Revive Therapeutics Ltd., Annual General Meeting, Dec 19, 2023

Revive Therapeutics Ltd. Announces Initiation of Novel Bucillamine Formulation Development

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of Covid-19

Revive Therapeutics Ltd. To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Ltd. Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of Covid-19

Revive Therapeutics Ltd. announced that it expects to receive CAD 5 million in funding from EMD Financial Inc.

Revive Therapeutics Ltd. announced that it expects to receive CAD 5 million in funding from EMD Financial Inc.

Revive Therapeutics Ltd. Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Revive Therapeutics Ltd. Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd., Annual General Meeting, Aug 03, 2022

Revive Therapeutics Ltd. Provides Update on U.S. Food & Drug Administration Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Announces Publication of Research Data with Bucillamine in Covid-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics Ltd. to Provide an Update on its Psychedelics Development and Clinical Programs with a Focus on Psilocybin

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

Revive Therapeutics Ltd. Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Ltd. Provides Update on Cannabinoid Pharmaceuticals Program

Revive Therapeutics Ltd., Annual General Meeting, Apr 05, 2021

Revive Therapeutics Announces Research Collaboration with North Carolina State University

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Revive Therapeutics Ltd. Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

Revive Therapeutics Ltd. Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Ltd. Announces Clinical Study of Psilocybin in the Treatment of Methamphetamine Use Disorder

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin